Home › Trial NCT05061628
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
- Trial IDNCT05061628
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorShanghai Junshi Bioscience Co., Ltd.
- Enrollment47
- Start date2021-04-21
- ConditionsAdvanced Tumors
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.